fenoldopam has been researched along with Heart Diseases in 1 studies
Fenoldopam: A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation.
Heart Diseases: Pathological conditions involving the HEART including its structural and functional abnormalities.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Stone, GW | 1 |
McCullough, PA | 1 |
Tumlin, JA | 1 |
Lepor, NE | 1 |
Madyoon, H | 1 |
Murray, P | 1 |
Wang, A | 1 |
Chu, AA | 1 |
Schaer, GL | 1 |
Stevens, M | 1 |
Wilensky, RL | 1 |
O'Neill, WW | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Renal Insufficiency Following Contrast Media Administration Trial II (Remedial II): The RenalGuard System in High-Risk Patients for Contrast-Induced Acute Kidney Injury[NCT01098032] | Phase 3 | 294 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The primary outcome measure will be the rate of development of CI-AKI in the 2 study arms (number of participants). CI-AKI is defined as an increase in the serum creatinine concentration >=0.3 mg/dL from the baseline value at 48 hours after administration of the contrast media or the need for dialysis. (NCT01098032)
Timeframe: at 48 hours following contrast exposure
Intervention | participants (Number) |
---|---|
Systemic Alone Therapy Group | 146 |
RenalGuard System Group | 146 |
1 trial available for fenoldopam and Heart Diseases
Article | Year |
---|---|
Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial.
Topics: Adult; Aged; Angiography; Angioplasty, Balloon, Coronary; Contrast Media; Creatinine; Dopamine Agoni | 2003 |